Treatment outcomes of metastasis-directed treatment using

Autor: Pervin, Hurmuz, Cem, Onal, Gokhan, Ozyigit, Sefik, Igdem, Banu, Atalar, Haluk, Sayan, Zuleyha, Akgun, Meral, Kurt, Hale Basak, Ozkok, Ugur, Selek, Ezgi, Oymak, Burak, Tilki, Ozan Cem, Guler, Teuto Zoto, Mustafayev, Irem, Saricanbaz, Rashad, Rzazade, Fadıl, Akyol
Rok vydání: 2020
Předmět:
Zdroj: Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]. 196(11)
ISSN: 1439-099X
Popis: The aim of this study was to evaluate the outcomes ofIn this multi-institutional study, clinical data of 176 PC patients with 353 lesions receiving MDT between 2014 and 2019 were retrospectively evaluated. All patients had biopsy proven PC with ≤5 metastases detected withAt the time of MDT, 59 patients (33.5%) had synchronous and 117 patients (66.5%) had metachronous metastases. Median number of metastases was one and the MDT technique was SBRT in 73.3% patients. The 2‑year overall survival (OS) and progression-free survival (PFS) rates were 87.6% and 63.1%, respectively. With a median follow-up of 22.9 months, 9 patients had local recurrence at the irradiated site. The 2‑year local control rate at the treated oligometastatic site per patient was 93.2%. In multivariate analysis, an increased number of oligometastases and untreated primary PC were negative predictors for OS; advanced clinical tumor stage, untreated primary PC, BED3 value of ≤108 Gy, and MDT with conventional fractionation were negative predictors for PFS. No patient experienced grade ≥3 acute toxicity, but one patient had a late grade 3 toxicity of compression fracture after spinal SBRT.
Databáze: OpenAIRE